ArticleBlood neoplasia2026

CPX-351 plus gemtuzumab ozogamicin in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.

Yesid Alvarado et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.